SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137Takayuki Kamikawa(Chugai Pharma (United States)), Tomoyuki Igawa(Chugai Pharma (United States))Journal for ImmunoTherapy of CancerOctober 1, 202410.1136/jitc-2024-009563Cited by 13SaveCiteExport RISWatch citationsRelated PapersEngineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer|Cancer Immunology Research|2024|22